Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size by Stier, Sebastian et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 201, No. 11, June 6, 2005 1781–1791 www.jem.org/cgi/doi/10.1084/jem.20041992
 
ARTICLE
 
1781
 
Osteopontin is a hematopoietic stem cell 
niche component that negatively regulates 
stem cell pool size
 
Sebastian Stier,
 
1,2,3
 
 Yon Ko,
 
3
 
 Randolf Forkert,
 
1,2,3
 
 Christoph Lutz,
 
1,2,3
 
 
Thomas Neuhaus,
 
3
 
 Elisabeth Grünewald,
 
3
 
 Tao Cheng,
 
1,2
 
 David Dombkowski,
 
1,2
 
 
 
Laura M. Calvi,
 
4
 
 Susan R. Rittling,
 
5
 
 and David T. Scadden
 
1,2
 
1
 
Center for Regenerative Medicine and Technology, Massachusetts General Hospital Cancer Center, 
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
 
2
 
Harvard Stem Cell Institute, Cambridge, MA 02138
 
3
 
Medizinische Poliklinik, University of Bonn, 53111 Bonn, Germany
 
4
 
Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642
 
5
 
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ 08854
 
Stem cells reside in a specialized niche that regulates their abundance and fate. Components 
of the niche have generally been defined in terms of cells and signaling pathways. We define 
a role for a matrix glycoprotein, osteopontin (OPN), as a constraining factor on 
hematopoietic stem cells within the bone marrow microenvironment. Osteoblasts that 
participate in the niche produce varying amounts of OPN in response to stimulation. Using 
studies that combine OPN-deficient mice and exogenous OPN, we demonstrate that OPN 
modifies primitive hematopoietic cell number and function in a stem cell–nonautonomous 
manner. The OPN-null microenvironment was sufficient to increase the number of stem cells 
associated with increased stromal Jagged1 and Angiopoietin-1 expression and reduced 
primitive hematopoietic cell apoptosis. The activation of the stem cell microenvironment 
with parathyroid hormone induced a superphysiologic increase in stem cells in the absence 
of OPN. Therefore, OPN is a negative regulatory element of the stem cell niche that limits 
the size of the stem cell pool and may provide a mechanism for restricting excess stem cell 
expansion under conditions of niche stimulation.
 
The stem cell niche is a specialized microenvi-
ronment that houses and regulates the stem cell
pool. In lower organisms, the niche incorporates
elements that support a primitive or stem cell
phenotype, as well as components that enforce
terminal differentiation and end cell cycling
among stem cell progeny. In this way, the 
 
Dro-
sophila melanogaster
 
 germ cell niche both nur-
tures and constrains stem cells, maintaining strict
control on stem cell number (1, 2). Whether
the same is true for mammalian stem cell
niches has not been well defined. Components
of stem cell niches have generally been defined
in terms of cells and molecular pathways. In
the murine hematopoietic stem cell niche, we
and Zhang et al. demonstrated that the osteo-
blast is a major niche constituent (3, 4). We
showed that activation of the osteoblast by para-
thyroid hormone (PTH)-R activation could in-
crease stem cell numbers mediated by Notch1.
Zhang et al determined that deleting BMPR1a
similarly increased osteoblasts and caused an
increase in stem cells. In both cases, the increase
in hematopoietic stem cells was no more than
twofold. Such an increase was demonstrated to
have a physiologic importance of surprising
uniformity given the varying means of osteo-
blast activation. 
We examined whether an osteoblast product
could account for this restriction on the stem
cell pool size and chose the osteoblast product
osteopontin (OPN) for several reasons. OPN
(also known as early T cell activation gene-1,
or 
 
eta-1
 
), is a secreted, highly acidic glycoprotein
with pleiotropic effects (5–11). OPN binds to
cells through an arginine-glycine-aspartate–
mediated interaction with integrins and non–
arginine-glycine-aspartate–mediated interactions
with CD44, activating multiple and varied sig-
naling pathways. Stem cells are known to ex-
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press CD44 and 
 
 
 
4 integrin, both of which are receptors ca-
pable of interacting with OPN (12, 13). Within bone, OPN
is expressed prominently at sites of bone remodeling and at
cell-lined bone surfaces such as the endosteum, providing a
potential context for stem cells encountering this glycopro-
tein (14). The absence of OPN does not affect bone mor-
phology, trabecular spaces associated with stem cell localiza-
tion, or osteoblasts under homeostatic conditions (15). In
addition to being produced by cells of osteoblastic lineage,
OPN has been shown to play important roles in chemotaxis,
adhesion, and proliferation, all of which allow it to mediate
inflammation and immunity to infectious diseases (16–19).
For example, granulomatous responses are associated with
high levels of OPN expression (16, 17, 20) and OPN can
function as a Th1 cell cytokine, enhancing IL-12 while in-
hibiting expression of the Th2 cell cytokine IL-10 (17, 19,
21). Furthermore, OPN can alter the sensitivity of hemato-
poietic cells to other cytokine stimuli (22). We reasoned that
the potential for OPN to affect stem cell function in the
niche was great given its abundance in the proper geo-
graphic location, its receptor expression on stem cells, and
the evidence for it affecting processes in other cells that
might be relevant for stem cell physiology.
We previously reported that OPN production is modu-
lated by osteoblast stimulation in vivo, resulting in dramati-
cally increased OPN abundance in the areas adjacent to tra-
becular bone known to serve as the anatomic location of
hematopoietic stem cells (3, 4). These data indicated that
OPN is produced in a regulated manner, a characteristic that
would be expected of a physiologic mediator of niche func-
tion. We therefore examined the role of OPN in the he-
matopoietic stem cell niche using genetically engineered
mice and exogenous OPN. We report that mice deficient in
OPN have an increased stem cell pool size in vivo. Without
OPN, there was no notable change in stem cell cycling, but
there was an increased expression of two ligands known to
modify stem cell function—the Notch1 ligand (Jagged1) and
the Tie-2 ligand (Angiopoietin-1)—accompanied by a de-
creased rate of stem cell apoptosis. Adding OPN to primitive
cells ex vivo directly increased their apoptotic fraction. The
ability of OPN to restrict stem cell numbers was emphasized
under conditions of osteoblast stimulation with PTH in
which the expansion of stem cells was increased in the ab-
sence of OPN. Therefore, OPN provides a constraining
function on stem cell numbers in the hematopoietic stem cell
niche and may provide a dampening effect to prevent excess
stem cell expansion during periods of niche stimulation.
 
RESULTS
Bone marrow OPN production is altered by PTHR activation 
on osteoblasts
 
To validate that OPN is produced in a modulated manner at
sites relevant for hematopoiesis, we performed immunohis-
tochemistry on tibia sections either from wild-type animals or
from animals with the activation of the PTHR. To focus spe-
cifically on the osteoblast production of OPN, we used mice
transgenic for a constitutively active PTHR driven by the os-
teoblast-specific collagen
 
 
 
1(I) promoter. Production of OPN
in the marrow cavity under normal homeostatic conditions
was generally in immediate proximity to spindle-shaped os-
teoblasts lining trabecular bone surfaces (Fig. 1). In contrast,
with activated PTHR, OPN staining was markedly increased
and extended diffusely from the trabecular surface into the in-
terstitium surrounding hematopoietic cells (Fig. 1). We previ-
ously demonstrated that osteoblasts were producing this in-
creased OPN using a combination of in situ hybridization and
immunohistochemistry (23). However, we noted that other
hematopoietic cells can also express OPN in response to cy-
tokine stimuli (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20041992/DC1). Collectively, these data
indicate that OPN is produced in varying amounts with the
resulting varied distribution affected by cell stimulation. Our
demonstration of varied OPN production by the known
niche constituent, the osteoblast, provides support to further
investigate the role of OPN in bone marrow homeostasis.
 
Expanded primitive cell pool in OPN-deficient mice
 
Initially, we characterized the bone marrow hematopoietic
compartment under steady-state conditions using animals en-
gineered to be deficient in OPN or their wild-type littermates
Figure 1. OPN is increased in bone marrow with the activation of 
osteoblasts. Immunohistochemistry of tibia sections from wild-type (left) 
or littermate transgenic (right) mice with a constitutively activated PTH/
parathyroid related peptide receptor driven by a 2.3-kb fragment of the 
collagen 1(I) promoter as previously described (reference 4). Sections 
were stained with antibody to osteopontin (red) and counterstained as de-
scribed (reference 4), and photographed at 200  (top) with  4  image 
zoom (bottom). Yellow arrows indicate OPN-rich spindle shaped cells lining 
the trabecular bone that is consistent with an osteoblast morphology. 
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as controls (15). The total cellularity (OPN
 
 
 
/
 
 
 
, 54.4 
 
 
 
 4.7 
 
 
 
10
 
6
 
 cells and OPN
 
 
 
/
 
 
 
, 51.4 
 
 
 
 3.8 
 
 
 
 10
 
6
 
 cells; P 
 
 
 
 0.31, 
 
n
 
 
 
 
 
9) and the proportion of differentiated cells such as B- and
T-lymphocytes, granulocytes, or erythroid cells were not al-
tered in the absence of OPN (Fig. 2 B). Therefore, OPN de-
ficiency has minimal impact on the steady state of more ma-
ture blood elements and similarly modest changes in precursor
populations as determined by quantitating cells without ma-
ture lineage markers (lin
 
 
 
; absolute numbers: OPN
 
 
 
/
 
 
 
, 2.6 
 
 
 
10
 
6
 
 
 
 
 
 0.2; and OPN
 
 
 
/
 
 
 
, 3.0 
 
 
 
 10
 
6
 
 
 
 
 
 0.3 per femur; P 
 
 
 
0.16, 
 
n
 
 
 
 
 
 8) or with markers of differentiating erythroblasts
(Ter119/CD71) or B cells (B220/IgM
 
 
 
 or B220/IgM
 
 
 
; Fig.
S2, available at http://www.jem.org/cgi/content/full/
jem.20041992/DC1). However, flow cytometric analyses re-
vealed significantly more primitive cells in the stem cell–
enriched Sca1
 
 
 
c-kit
 
 
 
lin
 
 
 
 cells in OPN-deficient mice com-
pared with controls (OPN
 
 
 
/
 
 
 
, 1.44 
 
 
 
 0.26% vs. OPN
 
 
 
/
 
 
 
,
2.64 
 
 
 
 0.58%; P 
 
 
 
 0.03, 
 
n
 
 
 
 
 
 8) (absolute number: 2.92 
 
 
Figure 2. Primitive hematopoietic cells are increased in the bone 
marrow of OPN /  mice, whereas mature cells are not. (A) Bone marrow 
cells of OPN /  (littermate control) and OPN /  mice were harvested, 
counted, and stained with the lineage-specific markers CD8, CD4, B220, 
Mac1 (CD11b), Gr-1, and Ter119 before flow cytometry. The graph shows 
the mean percentage   SEM (n   3). Bone marrow cells of OPN /  and 
OPN /  mice were stained with Sca1, c-kit, and lineage markers (CD3, 
CD4, CD8, B220, Gr-1, CD11b, and Ter119) for flow cytometry. The dot 
plots show the Sca1 c-kit  cells (top right) gated on lin  bone marrow 
cells for a single experiment (B) and for a summary of six mice in each 
group (C). (D) The highly stem cell–enriched CD34  portion of the
Sca1 c-kit lin  cells was evaluated in eight pairs of OPN /  (littermate 
control) and OPN /  mice by flow cytometry. The absolute number was 
calculated and is shown. (E) To confirm the immuno-phenotypic findings, 
we performed LTC-IC assays at limiting dilution and calculated the fre-
quency of LTC-ICs. The data shown are the mean frequency   SEM of
LTC-ICs per 100,000 bone marrow cells (P   0.01, n   5 pairs). (F) To con-
firm the LTC-IC data, we transplanted equal numbers of OPN-deficient 
(Ly5.2) and wild-type (Ly5.1) bone marrow of congenic mice into lethally 
irradiated wild-type recipients in a CRA. 12 wk after transplantation, the 
bone marrows of the recipient mice were analyzed for the contribution of 
Ly5.2 and Ly5.1 cells by flow cytometry with results shown (n   8). 
OSTEOPONTIN IS AN INHIBITORY NICHE COMPONENT | Stier et al.
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0.55 
 
 
 
 10
 
4
 
 vs. 4.68 
 
 
 
 1.12 
 
 
 
 10
 
4
 
 per femur pair; P 
 
 
 
 0.02,
 
n
 
 
 
 
 
 8; Fig. 2 C; reference 24). Within the Sca1
 
 
 
c-kit
 
 
 
lin
 
 
 
population, the CD34
 
 
 
 subset has been defined to further pu-
rify cells capable of long-term reconstitution; we found that
these cells were also considerably increased in the OPN-defi-
cient animals (P 
 
 
 
 0.02, 
 
n
 
 
 
 
 
 8; Fig. 2 D; reference 25).
To assess the impact on cells defined by function, we ini-
tially performed colony assays using the methylcellulose col-
ony-forming cell (CFC) assay for progenitors. A significantly
lower number of CFCs in the bone marrow of OPN
 
 
 
/
 
 
 
mice were noted (OPN
 
 
 
/
 
 
 
, 30.6 
 
 
 
 4.1 vs. OPN
 
 
 
/
 
 
 
, 19.05 
 
 
 
2.9 colonies per 104 bone marrow cells; P   0.025, n   5).
As a measure of more primitive cells, we performed long-
term cultures (LTCs) on primary murine bone marrow
stroma using a limiting dilution LTC–initiating cell (IC) as-
say. OPN /  bone marrow cells gave rise to a significantly
higher number of LTC-ICs (P   0.01, n   5; Fig. 2 E).
Notably, the OPN-null cells were able to mature into nor-
mal-appearing colonies on wild-type stroma used in these
assays, which suggests that OPN deficiency did not intrinsi-
cally impair hematopoietic cell differentiation.
To more accurately assess the impact of OPN on the
stem cell compartment, we admixed cells in a 1:1 ratio from
the wild-type and null genotypes and transplanted them into
lethally irradiated wild-type recipients. 12 wk after trans-
plantation, the relative abundance of each genotype was
quantitated, and the OPN /  cells represented 67.1   1.6%
(n   8) of the bone marrow and blood cells (Fig. 2 F). The
difference between the relative engraftment of OPN /  to
wild-type cells was highly statistically significant (P  
0.00001) and reflected an approximately twofold excess of
stem cells present in the OPN /  donor marrow. Prolifera-
tion, apoptosis, or other stem cell–autonomous effects could
all account for these results and were subsequently addressed.
Transplantation analysis demonstrates a stroma-determined 
effect by OPN on hematopoietic stem cells
To address whether the impact of OPN was stem cell au-
tonomous or stroma dependent, we performed sequential
bone marrow transplantation, reasoning that a stem cell–
autonomous effect would be retained with each transplant,
whereas a nonautonomous or stroma-determined effect
would not. Bone marrow from OPN /  or OPN /  male
animals (Ly5.2) was transplanted into lethally irradiated fe-
male Ly5.1  mice. 2 mo after engraftment, 4–8   106 bone
marrow cells were used as donor cells and again transplanted
Figure 3. OPN /  hematopoietic stem cell increase is not cell 
autonomous, but stroma dependent. (A) In a serial transplantation 
experiment using C57BL/6 wild-type mice (Ly5.1) as recipients for either 
OPN /  or OPN /  bone marrow (Ly5.2), OPN /  hematopoietic stem cells 
lost their advantage in numbers by the second transplantation, reverting 
to the OPN /  phenotype. Data are presented as the ratio of OPN / /
OPN /  with the mean absolute number of Sca1 c-kit lin  cells from five 
mice in each genotype at each transplantation. (B) OPN /  primitive 
hematopoietic cells have no advantage in homing to the bone marrow. 
Whole bone marrow cells of male OPN /  and OPN /  mice (Ly5.2) were 
transplanted into lethally irradiated female recipients (Ly5.1), and 16 h 
after transplantation, the bone marrow of the recipients was analyzed for 
Ly5.1 and Ly5.2 and differentiation markers. The graph shows that the 
approximately twofold increase in donor OPN /  Sca1 c-kit lin  cells 
was preserved in the marrow of recipients. (C–E) Primitive cell expansion 
in OPN /  mice is stroma dependent. In C, Sca1 lin  hematopoietic stem 
cells were isolated from wild-type bone marrow and plated on either 
wild-type or OPN-deficient stroma in limiting dilution LTC-IC assays 
(n   7). In D and E, wild-type bone marrow was transplanted into lethally 
irradiated OPN /  or OPN /  recipients. 12 wk after transplantation, the 
bone marrow cells of the recipient mice were analyzed by flow cytometric 
analyses and functional LTC-IC assays (n   4 for each assay). Error bars 
represent SEM.JEM VOL. 201, June 6, 2005 1785
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into new lethally irradiated Ly5.1  recipients. After another
3-mo period, the bone marrows of the secondary recipients
were analyzed. There was no difference in the total bone
marrow cellularity of animals serially transplanted with
OPN /  or OPN /  bone marrow cells. Similarly, there
was no difference in either the proportion or absolute num-
ber of the stem cell–enriched Sca1 kit lin  fraction of
Ly5.2  cells in the bone marrow of animals serially trans-
planted with OPN /  or OPN /  cells, suggesting the un-
altered self-renewal ability of OPN-deficient stem cells (Fig.
3 A). To more accurately quantify the progenitor and prim-
itive cell frequency in the bone marrow of the serially trans-
planted animals, we performed CFC and LTC-IC assays.
We could not detect any notable differences between geno-
types in either population as reflected by these assays (un-
published data). These data demonstrate that the alteration
in primitive hematopoiesis (increased LTC-ICs and de-
creased CFCs) seen in an OPN-deficient animal was not
persistent when cells from that animal were transplanted
into a wild-type background. Why the cell numbers would
revert back to a level resembling wild-type animals has sev-
eral possible explanations. It is possible that OPN /  stem
cells do not home as well as OPN /  cells, meaning that
fewer cells arrive at their supportive niche, which accounts
for the result.
To directly address the issue of abnormal homing of
seeding, we performed in vivo homing assays. Bone marrow
cells of OPN /  or OPN /  (Ly5.2) mice were transplanted
into lethally irradiated wild-type recipients (Ly5.1; 2   107
per animal). 14 h after transplantation, the recipient animals
were killed and the bone marrow was analyzed by flow cy-
tometry using the surface markers Ly5.1 and Ly5.2 simulta-
neously with stem cell markers. The proportion of donor
cells (Ly5.2) was similar in the bone marrow of animals
transplanted with OPN /  or OPN /  bone marrow
([OPN / ] 3.37   0.4% vs. [OPN / ] 2.66   0.2%; P  
0.08, n   3). However, the proportion of Sca1 lin  cells, a
more primitive subset (26), was twofold higher in the ani-
mals transplanted with OPN /  bone marrow compared
with the controls ([OPN / ] 1.03   0.1% vs. [OPN / ]
2.13   0.1%; P   0.001, n   3; Fig. 3 B), which reflected
the twofold higher proportion of stem cells in the bone mar-
row of the OPN /  donor animals before transplantation.
Therefore, OPN-deficient stem cells do not appear to have
any disadvantage in seeding or short-term (14 h) retention in
the bone marrow.
To assess the possible role of the microenvironment itself
in governing stem cell pool size, we cultivated stroma from
either OPN /  or OPN /  mouse bone marrow. Sca-1 
lin  mononuclear bone marrow cells from either genotype
Figure 4. OPN /  bone marrow has unaltered cell cycle profiles 
associated with increased stromal Jagged1 and Angiopoietin-1 
expression and reduced primitive cell apoptosis. (A) Bone marrow 
Sca1 c-kit lin  cells with a bright staining for Hoechst 33342, representing 
cells in the G2/M phase of the cell cycle (n   3 pairs). (B) BrdU incorpora-
tion in Sca1 c-kit lin  cells at the specified time points in OPN /  and 
OPN /  bone marrow. Data are the result of two independent experiments 
with four mice per group in each experiment. A Student’s t test compari-
son revealed no P   0.05. (C) Bone marrow adherent stromal cells were 
evaluated for Jagged1, Angiopoietin (Ang)-1, and N-cadherin expression 
by RT-PCR (n   6 for each). Data were normalized to an intrasample 
GAPDH standard, and the results of the OPN /  vs. OPN /  cells were 
compared by ratio. (D) Bone marrow cells of OPN /  and OPN /  mice 
were stained with antibodies to differentiation markers, the apoptosis 
marker Annexin V, and the DNA dye 7-AAD. Annexin V–positive/7-AAD–
negative apoptotic Sca1 c-kit lin  cells are shown (n   4 pairs). (E) 
Stroma-dependent apoptotic rate demonstrated by reduced apoptosis of 
wild type primitive hematopoietic cells when transplanted into OPN /  
mice compared with OPN /  recipient mice. Analyses were performed 
on the lin  fraction 12 wk after transplantation (n   4). Error bars 
represent SEM.OSTEOPONTIN IS AN INHIBITORY NICHE COMPONENT | Stier et al. 1786
were then plated at limiting dilutions in standard LTC-IC
conditions. The OPN /  stroma was more capable of sup-
porting LTC-ICs than wild-type stroma (365.5   60.2
LTC-ICs/100,000 cells vs. 450.4   63.1 LTC-ICs/100,000
cells; P   0.002, n   7; Fig. 3 C). These data suggested that
stroma was the determinant of primitive pool size and not the
primitive cells themselves. This nonautonomous effect on
primitive cells supported a role for OPN in the regulatory
microenvironment and we further investigated that role.
To test the in vivo effects of the OPN /  stroma, we
transplanted wild-type cells into lethally irradiated OPN / 
or OPN /  animals. 12 wk after engraftment, the relative
abundance of donor cells was examined by flow cytometry
and functional LTC-IC assays. Marrow that had been en-
grafted in the OPN-deficient hosts demonstrated a statis-
tically significant increase in phenotypic Ly5.2 Sca1 c-
kit lin  cells and functional LTC-ICs (4.72   0.11 vs.
5.63   0.49% of Sca1 c-kit  cells in the lin  fraction, P  
0.049,  n    4; 0.59   0.08 vs. 1.22   0.26 LTC-ICs/
100,000 cells, P   0.049, n   4; Fig. 3, D and E) closely re-
sembling the OPN-null phenotype. Therefore, the mi-
croenvironment provided by the OPN-deficient animals was
able to support a greater number of primitive cells in a
stroma-dependent manner. These data support the stem
cell–nonautonomous nature of the OPN /  effect.
OPN deficiency does not affect cell cycle kinetics, but alters 
stromal Jagged1 and Angiopoietin-1 expression and 
primitive cell apoptosis
To assess potential mechanisms by which the microenviron-
ment of the OPN-deficient animals contributed to the ex-
panded stem cell pool in OPN /  mice, we assessed cell cy-
cle kinetics. Bone marrow cells were stained with Sca1, c-kit,
and lineage markers, and the cell cycle status was analyzed by
simultaneous staining with the DNA dye Hoechst 33342.
We observed a similar G0/G1 and S G2/M percentage of
Sca1 c-kit lin  in the bone marrow of OPN /  and
OPN /  animals (S G2/M OPN / , 0.22 and OPN / ,
0.22%; pooled bone marrow of three animals each; Fig. 4 A).
These data indicate an unperturbed cell cycle status of primi-
tive cells in the absence of OPN even though it is recognized
that they cannot define the interval spent in any phase in a
single cycle, nor the rapidity of cycling. To better address the
latter issue, BrdU labeling was performed by exposing the an-
imals to BrdU in their drinking water for variable intervals
and examining the extent of BrdU uptake in primitive subsets
of marrow cells by flow cytometry. Modest differences that
did not achieve significance were noted between the geno-
types at 3, 6, and 10 d (Fig. 4 B).
Stem cell expansion may occur without increased prolif-
eration in the context of Notch1 activation where stem cell
self-renewal is favored over differentiation (27, 28). Activa-
tion of Notch1 on primitive hematopoietic cells in vivo was
previously shown by us to result in an increase in primitive
cells, but reduced progenitor cells; a similar phenotype was
observed here (27). Also, a link between Notch1 and OPN
was reported by Iwata et al., who showed that OPN can re-
duce Notch1 receptor abundance on human CD34  cells
(29). Because the Notch1 ligand, Jagged1, has been shown
to be produced by osteoblasts in the hematopoietic stem cell
niche and to affect stem cell pool size (4), we assessed the
Jagged1 expression in marrow stromal cells. An increase in
Jagged1 was observed in the OPN-deficient animals relative
to wild-type controls (P   0.02, n   6; Fig. 4 C). To deter-
mine whether the reciprocal was true—that OPN stimula-
tion of wild-type cells might decrease Jagged1—we exposed
marrow stroma to OPN ex vivo for 4 h. Jagged1 was
found to be significantly reduced statistically by OPN
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20041992/DC1). Other molecular features of the stem
cell niche recently defined include N-cadherin (3) and An-
giopoietin-1 (30). We also examined the expression of these
in stroma and noted modest, insignificant increases in
N-cadherin (P   0.08, n   6), but a more pronounced in-
crease in Angiopoietin-1 in the absence of OPN (P   0.02,
n   6; Fig. 4 C). Angiopoietin-1 has been defined as a mol-
ecule that can increase stem cells not by increasing prolifera-
tion, but rather by enhancing quiescence. These data suggest
that the impact of OPN expression is likely multifaceted; it
alters features of the niche that in combination change its ca-
pacity to nurture primitive hematopoietic cells, none of
which are associated with increased proliferation.
An additional possible mechanism for increasing stem
cell numbers without altering cycling kinetics is decreased
cell death. To evaluate this, bone marrow cells were
stained with stem cell markers and simultaneously with
Annexin V and the DNA dye 7-AAD to determine the
fraction of apoptotic cells indicated by the phenotype An-
nexin V 7-AAD . We could detect a trend toward fewer
apoptotic cells in the Sca1 c-kit lin  bone marrow stem
cell–enriched population in OPN /  mice in comparison
with controls (n   4). Additionally, the OPN-deficient
bone marrow in serially transplanted animals showed a
lower fraction of apoptotic cells in the Sca1 c-kit lin 
cell population in comparison with controls, suggesting a
preserved lower tendency of OPN-deficient stem cells to
become apoptotic. Furthermore, we transplanted wild-
type bone marrow into either the wild type or OPN-defi-
cient recipients and noted that lineage-negative hemato-
poietic cells of the OPN /  genotype acquired a decreased
apoptosis fraction similar to the OPN-deficient animal
(Fig. 4 D), demonstrating that the basis for the change in
apoptosis was stroma dependent. These results suggest that
the enlarged stem cell pool in OPN-deficient mice may
be caused, in part, by enhanced survival, but required fur-
ther definition.
Soluble OPN reduces LTC-ICs and increases the apoptotic 
fraction of wild-type cells
We used exogenous OPN to assess its potential role in regu-
lating primitive cells directly rather than through the altered
expression of other regulators within the niche. Initial ex-JEM VOL. 201, June 6, 2005 1787
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periments used Sca1 lin  bone marrow cells of C57BL/6
mice cultured in a medium containing stem cell factor
(SCF), Flt-3, TPO, and IL-3 with and without OPN for 7 d,
after which the cells were counted and analyzed in func-
tional in vitro progenitor and stem cell assays. The addition
of soluble OPN led to a lower total cell number with an un-
perturbed absolute number of CFCs representing hemato-
poietic progenitor cell activity (n   5; Fig. 5 A). However,
exogenous OPN led to a significantly lower absolute num-
ber of LTC-ICs (without OPN, 35.9   5.14 LTC-ICs/
well; with OPN, 16.41   4.5 LTC-ICs/well; P   0.002,
n   5; Fig. 5 B).
We next analyzed the fraction of apoptotic cells by
staining with lineage markers, 7-AAD and Annexin V,
and detected a higher percentage of Annexin V 7-AAD 
cells in the lin  cell population cultured with OPN,
which was consistent with increased apoptosis (Fig. 5 C).
A similar effect was seen with Sca  lin  cells in the
OPN /  animals and was neutralized with anti–OPN-
specific antibody (unpublished data). Therefore, the addi-
tion of OPN documented an effect on primitive cell
apoptosis that had been suggested by the analysis of the
OPN-deficient mice in vivo. OPN exerts a proapoptotic
effect on primitive cells, potentially constraining the size
of the stem cell pool.
OPN restricts primitive cell expansion induced by 
osteoblast activation
To determine whether OPN acts to limit the dimensions of
the stem cell pool under conditions in which stem cell expan-
sion occurs, we took advantage of a previously reported in vivo
context. PTH is capable of activating niche osteoblasts and, in a
Notch-mediated manner, expand the number of stem cells in
vitro and in vivo (4). PTH has been shown to be physiologi-
cally increased in settings such as myelotoxic ablation with ra-
diation and chemotherapy (31). Stimulation with PTH in-
creases OPN production, so we hypothesized that the degree
of stem cell expansion possible by PTH niche activation may
Figure 5. Soluble OPN induces apoptosis of primitive hematopoietic 
cells. Sca1 lin  cells were isolated from the bone marrow of C57BL/6 
mice and cultured in IMDM containing 10% FCS, SCF, Flt-3, TPO, and IL-3 
with or without 1  g/ml OPN. After 7 d, the cells were counted and ana-
lyzed in functional hematopoietic assays. (A) Soluble OPN did not alter the 
absolute number of CFCs per well in comparison with controls. Chart 
shows the total number of CFCs per well of five independent experiments 
(continuous lines) and the mean of all experiments (dotted line). (B) A 
decreased primitive cell activity could be detected in cells stimulated with 
OPN in comparison to controls. Chart shows the total number of LTC-ICs 
per well of five independent experiments (continuous lines) and the mean 
of all experiments (dashed line). (C) Cultured cells were stained with 
lineage markers, Annexin V, and 7-AAD. The chart shows the mean 
percentage   SEM of lin 7-AAD Annexin V  cells representing apoptotic 
primitive hematopoietic cells.
Figure 6. OPN deficiency permits increased primitive hematopoietic 
cell compartment expansion after niche activation by PTH. OPN /  
and OPN /  mice were treated with PTH by daily injection for 4 wk. The 
bone marrow was analyzed by flow cytometry. The graph shows the aver-
age of absolute numbers of Sca1 c-kit lin  stem cells per mouse without 
and with PTH stimulation in OPN /  (littermate control) and OPN /  mice 
(n   3 or 4). Numbers indicate the difference in absolute numbers of bone 
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be restricted by OPN. Using an OPN-null or wild-type
mouse, we assessed the number of primitive cells after 4 wk of
PTH stimulation. There was the expected difference in the
number of Sca1 c-kit lin  between the OPN-null and wild-
type mouse before PTH (Fig. 6). With PTH treatment, there
was an increase in the Sca1 c-kit lin  cells in each genotypic
background. The magnitude of Sca1 c-kit lin  increase in-
duced by PTH was greater in both proportion and absolute
number in the null animals (10.0 vs. 7.5%, or 5.94   104 vs.
3.82   104 stem cells per femur pair). These data indicate that
activation of the niche can increase primitive cells to a greater
degree without OPN present in the milieu, arguing that OPN
limits the degree of primitive cell increase that can be attained
with the stimulation of osteoblasts.
DISCUSSION
The stem cell niche provides a specialized regulatory envi-
ronment that includes signals to maintain the stem cell pool,
protecting it from exhaustion during the life of an organism.
Similarly, it provides a context in which stem cells are
pushed to differentiate, and it appears to limit the size of the
stem cell pool, presumably because of some selective pres-
sure against an excessively abundant stem cell mass. In or-
ganisms such as Drosophila, for example, it is well defined
that contact of stem cells with hub cells in the germarium are
required for the preservation of stem cells (2). If daughter
cells are not in contact with the hub cell, they undergo en-
forced differentiation, resulting in the cessation of cell cy-
cling. In this manner, there is a balance between primitive
and differentiated cells, and the size of the primitive popula-
tion does not go beyond the nurturing context of hub cell
contact, enforcing a tight control on stem cell number.
In mammalian systems, a similar regulatory relationship
has not been previously defined. The data we present indicate
that OPN is modulated in expression by stimulation of the
PTHR in osteoblasts as has been previously described by us
and others (4). The production appears to extend OPN be-
yond that of the immediate periosteoblast area and into
stroma away from the endosteal surface. The absence of OPN
results in an increase in the number of stem cells and the abil-
ity to increase primitive cell production when the PTHR is
activated. These data are consistent with a model in which
OPN restricts the stem cell population; without this mecha-
nism of constraint, expansion exceeds the usual level. Because
the relative increase was modest, the data suggest that OPN is
not alone in constraining stem cell pool size and that other
products of the niche may provide further restriction.
The increase in stem cells when OPN was absent was
caused by a microenvironmental effect rather than a stem
cell–autonomous effect. The effect was not restricted to the
bone marrow, as LTC-ICs were also noted to be increased
in the spleen (unpublished data), an observation that also in-
dicates the change in stem cell pool size was not due simply
to redistribution. Localization was one mechanism of OPN
action that might have been anticipated given that OPN can
engage a number of receptors, including the integrins
 v( 1, 3, or  5) and ( 4,  5,  8, or  9) 1, and is a ligand for
certain variant forms of CD44, specifically v6 and/or v7 (10,
32–35). CD44 and integrin  4 are expressed on primitive
hematopoietic progenitor cells and play physiologic roles in
stem cell localization (36, 37). Yet, the effects of OPN we
noted were not associated with altered homing. Nor was
there evidence for an altered cycling profile as has been ob-
served in other settings, resulting in expanded stem cell
numbers, such as p21Cip1 or p18INK4c deficiency (38, 39),
or HoxB4 (40) or Bmi-1 overexpression (41). The alteration
could be caused by a number of influences. One that we
showed could be a direct effect of OPN is apoptotic rate,
though it is more likely that there is combinatorial effect
contributed to by other features of the niche we also defined
as altered, including Jagged1 and Angiopoietin-1. Increased
local production of Jagged1 could alter Notch1 activation
and affect self-renewal. 
However, it should be noted that there did not appear to
be stem cell– or hematopoietic cell–autonomous changes in
self-renewal as evident in the serial transplantation studies in
which OPN-null stem cells failed to demonstrate persistent
increased cell numbers when transplanted into wild-type
hosts. Whether there is any link between the findings of de-
creased apoptosis and up-regulation of Jagged1 or Angiopoi-
etin-1 in the absence of OPN cannot be discerned from our
current data. We have previously demonstrated that activa-
tion of Notch1 in hematopoietic stem cells can result in an
increased stem cell pool size in vivo with reduced primitive
cell production of colonies similar to the phenotype of OPN
null (27); others have reported that Notch1 activation can
prevent hematopoietic cell death (42). Angiopoietin-1 has
been shown to enhance stem cell interactions with matrix
and cell components of the niche (30, 43, 44) and to en-
hance stem cell survival under stress (30). Altogether, these
studies suggest a possible indirect mechanism by which OPN
deficiency can change primitive cell populations by altering
Jagged1 or Angiopoietin-1 expression. However, our data
also argue for a functional contribution of OPN directly.
Exogenous OPN provided a proapoptotic stimulus in primi-
tive cells that was abrogated with neutralizing antibody to
OPN. Therefore, direct and indirect mechanisms likely con-
tribute to the in vivo phenotype of OPN null and genera-
tion of dually deficient animals is in progress to sort out the
relative contribution of each.
The data presented here extend the general concept of
matrix proteins regulating neighboring cell functions to that
of the stem cell niche. The participation of matrix proteins
in creating specialized microenvironments for stem cells that
participate in regulating the stem cell pool size adds a novel
dimension to the physiologic roles of extracellular matrix
constituents. A recent report indicates that the matrix pro-
tein, tenascin C, is needed for the proper number and po-
tential of primitive neural cells to be established in the sub-
ventricular zone of the central nervous system, indicating
that extracellular matrix can participate in mammalian stem
cell niches (45). We add the additional finding that a matrixJEM VOL. 201, June 6, 2005 1789
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protein that is modulable in its production may add a barrier
to stem cell expansion upon niche stimulation. Therefore,
extracellular matrix components may play a dynamic role
not just in establishing the stem cell pool size, but in govern-
ing its responsiveness to expansion signals.
MATERIALS AND METHODS
Cells and cell culture.  Mouse bone marrow was obtained from 8–12-
wk-old 129/C57BL/6 OPN /  and 129/C57BL/6 OPN /  mice killed
with CO2. Experiments were performed with the permission of the sub-
committee on Research Animal Care of the Massachusetts General Hospi-
tal. BM and spleen cell suspensions were flushed from femurs and tibias, or
taken from spleens, and filtered through a 100- m mesh nylon cloth (Sefar
America Inc.) and stored on ice until use.
Sca1 lin  BM WT cells were obtained from 6–8-wk-old C75Bl/6
mice. BM cells were washed and stained with Sca1  microbeads (Miltenyi
Biotec) and biotinylated lineage antibodies (CD3, CD4, CD8, Gr-1, Mac-1,
B220, and Ter119; BD Biosciences). A positive selection for Sca1  cells,
followed by a negative selection for Sca lin  cells, using streptavidin micro-
beads was performed according to the manufacturer’s instructions (Miltenyi
Biotec). The cells were cultured in IMDM (GIBCO BRL) containing 10%
FCS, 50 ng/ml SCF, 50 ng/ml Flt-3, 25 ng/ml TPO, and 10 ng/ml IL-3
(R&D Systems). OPN protein was obtained from R&D Systems.
Colony forming assay.  This assay was used to measure the CFC as de-
scribed in our previous publication (38). Murine SCF was used in this study
instead of human SCF and cells were plated at only 500 cells/ml.
LTC with limiting dilutions.  To quantify the stem cells in the bone
marrow and spleen cell suspension, we adapted the colony forming assay
(46) with minor modifications, as described in our previous publication
(47). To measure LTC-ICs, the semisolid cytokine-containing methylcellu-
lose medium for CFC was overlaid into the wells at week 5 and the colo-
nies were counted at day 10. A limiting dilution analysis software program
(Maxrob; provided by J. Down, BioTransplant Inc., Charlestown, MA) was
used to calculate the frequency of LTC-ICs in the cell population.
Competitive repopulation assay (CRA).  The CRA was used to eval-
uate the repopulation ability of the OPN /  BM in irradiated recipient
mice (48, 49). Recipient animals (female, C57BL/6-Ly5.1; The Jackson
Laboratories) were irradiated with a single dose of 10 Gy 12–16 h before
transplantation. The BM donor cells were obtained from 8–10-wk-old male
129/C57BL/6 OPN /  and 129/C57BL/6 OPN /  mice and prepared as
in Cells and cell culture section. All leukocytes of these mice are Ly5.2 pos-
itive. Congenic competitive BM cells (Ly5.1) were prepared as single cell
suspensions from male mice. A mixture of equal amounts of cells of the
OPN /  BM cells along with congenic Ly5.1 BM cells were resuspended
in Medium 199 and i.v. injected into the lateral tail vein of lethally irradi-
ated Ly5.2 WT or OPN /  female recipients (n   5 per group). The mice
were killed and BM cells were prepared from those mice and analyzed by
flow cytometry.
Serial BM transplantation. Serial BM transplantation was used to evalu-
ate the ability of stem cells to self-renew. The BM donor cells were ob-
tained from 8–10-wk-old male 129/C57BL/6 OPN /  and 129/C57BL/6
OPN /  mice and transplanted into lethally irradiated WT congenic recip-
ients (Ly5.1). The transplanted mice were killed at 2 mo and the BM was
prepared from those mice. New female recipient mice (n   5 per group)
were lethally irradiated and transplanted with 4   106 mononuclear BM
cells of the killed animals by injection in lateral tail veins. After 2 mo, BM
cells were harvested from these transplanted mice, analyzed by flow cytom-
etry, and again transplanted into lethally irradiated recipients (second trans-
planted mice). This process was repeated 2 mo later (third transplanted
mice), and CFC and LTC-IC assays were performed.
In vivo PTH treatment.  6–8-wk-old WT or null male mice were i.p.
injected with rat PTH (1–34; 80  g/kg of body weight; Bachem) or vehi-
cle alone five times per week for 4 wk (n   4–6 per group). Animals were
killed, and BM cells were isolated and analyzed as in Flow cytomeric analy-
sis section.
Flow cytometric analysis.  Flow cytometry was used to quantify the he-
matopoietic cells at different stages in the peripheral blood and BM of the
transplanted animals. BM nucleated cells were labeled with leukocyte anti-
bodies (Ly5.1-PE and Ly5.2-biotin; BD Biosciences), lineage antibodies
(CD3-PerCP, CD4-PE, B220-PE, Ter119-PE [BD Biosciences]; CD8-Tri,
Gr-1-Tri, Mac1-PE [Caltag]), and stem cell markers (Sca1-Tri and PE,
c-kit-Tri; Caltag). To quantify the enriched stem cell phenotype (Sca1 lin )
in primary animals and in transplanted animals, BM cells were stained with
biotinylated lineage antibodies (CD3, Ter119 [BD Biosciences]; CD4,
CD8, B220, IgM, Gr-1, and Mac1 [Caltag]), c-kit-APC (BD Biosciences),
and Sca1-PE (Caltag). The cells were analyzed after labeling with the sec-
ondary antibody Streptavidin-PerCP (Becton Dickinson). For cell cycle
analyses, BM cells were incubated with stem cell markers and the DNA dye
Hoechst33342. The proportion of apoptotic cells was measured by staining
with Annexin V (Caltag) and the DNA dye 7-AAD (Sigma-Aldrich).
Expression of Jagged1, Angiopoietin-1, N-cadherin, and OPN.
The expression of Jagged1, Angiopoietin-1, and N-cadherin in BM stroma
cells was measured by RT-PCR. Bone marrow stroma cells of OPN / 
and OPN /  mice were cultured for 3–6 wk in LTC medium and irradi-
ated with 10 Gy to abolish any hematopoietic activity in the culture. After
3 d, cells were lysed with TRI reagent and RT-PCR was performed as pre-
viously described (50). The following primers were used: Jagged1, 5 -GTG-
TGCCTCAAGGAGTATCAG-3  and 5 -CATAGTAGTGGTCATCA-
CAGG-3 ; Angiopoietin-1, 5 -GGATTCAACATGGGCAATGTG-3  and
5 -GGTTCCTATCTCAAGCATGG-3 ; N-cadherin, 5 -GCAGATTT-
CAAGGTGGACG-3  and 5 -CAGACCTGATTCTGACAAGC-3 ; and
OPN, 5 -CAAAGTCAGCCGTGAATTCCA-3  and 5 -AACCCAATA-
AACTGAGAAAGAAGC-3 . PCR of the reverse transcribed RNA was
performed using 25 cycles for Jagged1 and Angiopoietin-1, and 27 cycles
for N-cadherin. GAPDH transcripts were amplified in 25 PCR cycles. The
ethidium bromide–stained gels were photographed and the densitometric
results of gene expression were standardized to that of GAPDH expression
in the same sample.
OPN expression in primitive hematopoietic (LKS) cells was performed
as above after culture of the cells in IMDM (GIBCO-BRL) containing 10%
FCS, 50 ng/ml SCF, 50 ng/ml Flt-3, 25 ng/ml TPO, and 10 ng/ml IL-3
(R&D Systems) for the indicated times (Fig. S1).
Statistical analysis.  The significance of the difference between groups in
the in vitro and in vivo experiments was evaluated by analysis of variance
followed by a one-tailed Student’s t test.
Online supplemental materials. Evidence from RT-PCR analysis that
LKS cells express OPN mRNA with stimulation is provided in Fig. S1.
Also provided are the results of flow cytometry comparing the IgM  and
IgM  B220  populations of the WT and OPN /  animals (Fig. S2). These
data demonstrate no difference between the genotypes for either subset of
cells. Fig. S3 shows that the expression of Jagged1 relative to GAPDH de-
creases by RT- PCR analysis when WT stromal cells are exposed to 1  g/
ml OPN for 4 h ex vivo. Online supplemental material is available at http:
//www.jem.org/cgi/content/full/jem.20041992/DC1.
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